Review of current protocols for protontherapy in USA

Marco Krengli, Norbert J. Liebsch, Eugen B. Hug, Roberto Orecchia

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The basis for interest in proton beams by clinical radiation oncologists lies in reduction in treatment volume. The yields from employing a smaller treatment volume are the increase of tumor control probability and the reduction of normal tissues complication probability. The clinical use of proton therapy began in 1954 at Uppsala University in Sweden and in 1961 at Harvard Cyclotron Laboratory in Boston, USA. So far, the total number of worldwide patients treated by protons is about 20,000. In this paper attention will be given to the treatment of patients at the Massachusetts General Hospital-Massachusetts Eye and Ear Infirmary-Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center. In particular, a review of the literature about the techniques and the results of treatment of skull base and cervical spine chordoma and low-grade chondrosarcoma, skull base meningioma, pituitary tumors, paranasal sinus carcinoma, glioblastoma multiforme, artero-venous malformations, uveal melanoma, macular degeneration, retinoblastoma, thoracic spine-sacrum tumors, and prostate carcinoma is presented. In order to verify and improve the clinical results, the conduct of prospective trials on an inter-institutional basis is essential. To facilitate the conduct of such studies the US National Cancer Institute and the American College of Radiology have established the Proton Therapy Oncology Group (PROG). Several phase III and some phase I-II trials are active at the Massachusetts General Hospital, Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center.

Original languageEnglish
Pages (from-to)209-216
Number of pages8
JournalTumori
Volume84
Issue number2
Publication statusPublished - Mar 1998

Fingerprint

Cyclotrons
Loma
Proton Therapy
Skull Base
General Hospitals
Protons
Spine
Carcinoma
Chordoma
Sacrum
Chondrosarcoma
National Cancer Institute (U.S.)
Retinoblastoma
Paranasal Sinuses
Macular Degeneration
Pituitary Neoplasms
Meningioma
Therapeutics
Glioblastoma
Tumor Burden

Keywords

  • Clinical trials
  • Neoplasms
  • Protontherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Krengli, M., Liebsch, N. J., Hug, E. B., & Orecchia, R. (1998). Review of current protocols for protontherapy in USA. Tumori, 84(2), 209-216.

Review of current protocols for protontherapy in USA. / Krengli, Marco; Liebsch, Norbert J.; Hug, Eugen B.; Orecchia, Roberto.

In: Tumori, Vol. 84, No. 2, 03.1998, p. 209-216.

Research output: Contribution to journalArticle

Krengli, M, Liebsch, NJ, Hug, EB & Orecchia, R 1998, 'Review of current protocols for protontherapy in USA', Tumori, vol. 84, no. 2, pp. 209-216.
Krengli M, Liebsch NJ, Hug EB, Orecchia R. Review of current protocols for protontherapy in USA. Tumori. 1998 Mar;84(2):209-216.
Krengli, Marco ; Liebsch, Norbert J. ; Hug, Eugen B. ; Orecchia, Roberto. / Review of current protocols for protontherapy in USA. In: Tumori. 1998 ; Vol. 84, No. 2. pp. 209-216.
@article{c6e88f4612694177927e0c94289c70f2,
title = "Review of current protocols for protontherapy in USA",
abstract = "The basis for interest in proton beams by clinical radiation oncologists lies in reduction in treatment volume. The yields from employing a smaller treatment volume are the increase of tumor control probability and the reduction of normal tissues complication probability. The clinical use of proton therapy began in 1954 at Uppsala University in Sweden and in 1961 at Harvard Cyclotron Laboratory in Boston, USA. So far, the total number of worldwide patients treated by protons is about 20,000. In this paper attention will be given to the treatment of patients at the Massachusetts General Hospital-Massachusetts Eye and Ear Infirmary-Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center. In particular, a review of the literature about the techniques and the results of treatment of skull base and cervical spine chordoma and low-grade chondrosarcoma, skull base meningioma, pituitary tumors, paranasal sinus carcinoma, glioblastoma multiforme, artero-venous malformations, uveal melanoma, macular degeneration, retinoblastoma, thoracic spine-sacrum tumors, and prostate carcinoma is presented. In order to verify and improve the clinical results, the conduct of prospective trials on an inter-institutional basis is essential. To facilitate the conduct of such studies the US National Cancer Institute and the American College of Radiology have established the Proton Therapy Oncology Group (PROG). Several phase III and some phase I-II trials are active at the Massachusetts General Hospital, Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center.",
keywords = "Clinical trials, Neoplasms, Protontherapy",
author = "Marco Krengli and Liebsch, {Norbert J.} and Hug, {Eugen B.} and Roberto Orecchia",
year = "1998",
month = "3",
language = "English",
volume = "84",
pages = "209--216",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Review of current protocols for protontherapy in USA

AU - Krengli, Marco

AU - Liebsch, Norbert J.

AU - Hug, Eugen B.

AU - Orecchia, Roberto

PY - 1998/3

Y1 - 1998/3

N2 - The basis for interest in proton beams by clinical radiation oncologists lies in reduction in treatment volume. The yields from employing a smaller treatment volume are the increase of tumor control probability and the reduction of normal tissues complication probability. The clinical use of proton therapy began in 1954 at Uppsala University in Sweden and in 1961 at Harvard Cyclotron Laboratory in Boston, USA. So far, the total number of worldwide patients treated by protons is about 20,000. In this paper attention will be given to the treatment of patients at the Massachusetts General Hospital-Massachusetts Eye and Ear Infirmary-Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center. In particular, a review of the literature about the techniques and the results of treatment of skull base and cervical spine chordoma and low-grade chondrosarcoma, skull base meningioma, pituitary tumors, paranasal sinus carcinoma, glioblastoma multiforme, artero-venous malformations, uveal melanoma, macular degeneration, retinoblastoma, thoracic spine-sacrum tumors, and prostate carcinoma is presented. In order to verify and improve the clinical results, the conduct of prospective trials on an inter-institutional basis is essential. To facilitate the conduct of such studies the US National Cancer Institute and the American College of Radiology have established the Proton Therapy Oncology Group (PROG). Several phase III and some phase I-II trials are active at the Massachusetts General Hospital, Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center.

AB - The basis for interest in proton beams by clinical radiation oncologists lies in reduction in treatment volume. The yields from employing a smaller treatment volume are the increase of tumor control probability and the reduction of normal tissues complication probability. The clinical use of proton therapy began in 1954 at Uppsala University in Sweden and in 1961 at Harvard Cyclotron Laboratory in Boston, USA. So far, the total number of worldwide patients treated by protons is about 20,000. In this paper attention will be given to the treatment of patients at the Massachusetts General Hospital-Massachusetts Eye and Ear Infirmary-Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center. In particular, a review of the literature about the techniques and the results of treatment of skull base and cervical spine chordoma and low-grade chondrosarcoma, skull base meningioma, pituitary tumors, paranasal sinus carcinoma, glioblastoma multiforme, artero-venous malformations, uveal melanoma, macular degeneration, retinoblastoma, thoracic spine-sacrum tumors, and prostate carcinoma is presented. In order to verify and improve the clinical results, the conduct of prospective trials on an inter-institutional basis is essential. To facilitate the conduct of such studies the US National Cancer Institute and the American College of Radiology have established the Proton Therapy Oncology Group (PROG). Several phase III and some phase I-II trials are active at the Massachusetts General Hospital, Harvard Cyclotron Laboratory, and at the Loma Linda University Medical Center.

KW - Clinical trials

KW - Neoplasms

KW - Protontherapy

UR - http://www.scopus.com/inward/record.url?scp=0031779317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031779317&partnerID=8YFLogxK

M3 - Article

C2 - 9620247

AN - SCOPUS:0031779317

VL - 84

SP - 209

EP - 216

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -